What's Happening?
bioAffinity Technologies has announced a significant increase in sales for its CyPath® Lung diagnostic test, reporting a 146% growth in the first quarter of 2026 compared to the same period in 2025. This surge is attributed to the growing adoption of the test by
physicians seeking noninvasive methods for lung cancer risk assessment and nodule management. The CyPath® Lung test utilizes flow cytometry combined with artificial intelligence to provide a binary result indicating the likelihood of malignancy. The U.S. market for pulmonary nodule management and lung cancer surveillance is expanding, with projections indicating a rise in detected pulmonary nodules from 2.9 million in 2025 to 4.7 million by 2030. bioAffinity Technologies aims to capture a significant portion of this market, with potential sales reaching $560 million over the next five years.
Why It's Important?
The increase in CyPath® Lung test sales highlights a shift towards noninvasive diagnostic tools in the healthcare industry, particularly for lung cancer, which remains a leading cause of cancer-related deaths. The test's ability to detect lung cancer at an early, more treatable stage could significantly improve patient outcomes and reduce the need for invasive procedures. As the number of lung cancer survivors and individuals with indeterminate pulmonary nodules grows, the demand for reliable diagnostic tools is expected to rise. This trend underscores the importance of integrating advanced technologies like AI in medical diagnostics, potentially leading to more personalized and effective healthcare solutions.
What's Next?
bioAffinity Technologies plans to continue expanding the clinical use of CyPath® Lung by increasing the number of ordering physician sites and integrating the test into clinical workflows. The company is also conducting a large-scale longitudinal clinical study to further validate the test's effectiveness. Additionally, bioAffinity is exploring the development of diagnostic tests for other respiratory conditions, such as asthma and COPD, which could broaden its market reach and impact. As the company advances its commercialization strategy, it aims to solidify its position in the growing market for noninvasive cancer diagnostics.
